Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
Korro Bio is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA. By leveraging its proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform, the company aims to discover and develop therapies for rare and highly prevalent diseases. Korro Bio harnesses the body's natural RNA editing machinery to make precise, single-base edits, addressing...
The future of health is fast paced and complex, demanding a different approach. Established in 2001, our 1,300+ healthcare experts, combine their knowledge and expertise across our 4 core disciplines — Consulting; Medical; Marketing; and Policy, Access, Value, & Evidence. Working across the product and service lifecycle, from R&D to post launch, we engage our collective force to solve the complex...
At Swoop, we are driven by a bold mission that transcends traditional data analytics — we aim to create a future where technology seamlessly connects patients and healthcare providers throughout their health journey. As pioneers in healthcare engagement, we leverage our platform’s cutting-edge AI and machine learning capabilities, combined with deep industry expertise, to revolutionize how healthcare brands connect with...
Vcare Pharmacy is a chain of pharmacies that provides high-quality healthcare services and medications to people in need. With a focus on customer satisfaction, Vcare Pharmacy is committed to providing convenient, affordable, and reliable healthcare services to its customers. One of the main goals of Vcare Pharmacy is to improve access to healthcare for all people, regardless of their background or...
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring...
Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale
Resilience (resilience.com).'s Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company is described as well-funded, with multiple sizable financing events including up to $825M in long-term financing to accelerate its CDMO strategy and prior large equity rounds. Public-sector funding and government-backed initiatives are also cited as signals of confidence in its role in domestic manufacturing and supply-chain resilience.
Strategic Partnerships: The business has landed recognizable relationships such as an AstraZeneca fill/finish deal and earlier work with Takeda, which help validate its capabilities and quality expectations. Additional collaborations with research institutions are positioned as strengthening its advanced-therapy offering.
Future-Ready Strategy: The operating model is oriented toward complex modalities (biologics, vaccines, nucleic acids, cell and gene therapy) with drug substance and fill/finish capabilities, positioning it toward segments expected to remain strategically important. The post-2025 pivot toward a smaller set of “go-forward” hubs is framed as a refocus on higher-demand areas like sterile drug product and selected biologics/cell-therapy capabilities.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
Lyra Therapeutics is a clinical-stage biotechnology company developing long-acting, locally delivered anti-inflammatory implants to treat chronic rhinosinusitis (CRS). The company designs bioabsorbable drug-eluting matrices that release steroid therapy directly to sinonasal tissues for sustained relief, advancing lead candidates (LYR-210 and LYR-220) through late-stage clinical trials and pursuing commercialization and strategic alternatives to benefit CRS patients.
The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs
EdenRoc Sciences is a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies. EdenRoc specializes in enabling efficient translation of top tier academic and government science into technologies which provide novel and cutting-edge research tools, diagnostics, and pharmaceuticals.
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The...
Konovo is a global healthcare intelligence company on a mission to transform healthcare research by connecting insights across the life science ecosystem. Originally launched in 2019 as Apollo Intelligence, Konovo was born out of the combined capabilities of three industry-leading healthcare research firms: InCrowd, Survey Healthcare Global (SHG), and GlocalMind. Konovo’s 300+ employees support top global pharmaceutical and healthcare brands, market...
Massachusetts College of Pharmacy and Health Sciences (MCPHS) is an innovator in health and professional education, preparing future generations of global leaders to improve public health. With over 7,000 students across campuses in Boston, Worcester, and Manchester, MCPHS is one of the largest and most highly-ranked institutions for health and life sciences, dedicated to advancing the healthcare landscape through education...
At Synaptiq Health, we are deeply passionate about advancing life-changing therapies and services. As a collective of specialised agencies, including Emotive, Initiate, and Beyond PR, we bring together unparalleled expertise across Medical Communications, Market Access & HEOR, and PR & Advocacy. Our dedicated teams partner with top global pharmaceutical, biopharma, and biotechnology companies, as well as influential medical societies and health...
